Clinical Trials for Non-Small Cell Lung Cancer

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with 1-8 intact (unresected), non-brainstem brain metastases from solid tumors (such as NSCLC, melanoma, breast, renal, or GI cancers), good performance status, and no prior brain radiotherapy are randomized to receive either single-session stereotactic radiosurgery (SRS) or fractionated SRS (three sessions). Both approaches are non-invasive, high-precision outpatient radiotherapy options for brain metastases.

ClinicalTrials.gov ID: NCT06500455

Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced, metastatic, or unresectable melanoma, small cell or non-small cell lung cancer, or squamous cell head and neck cancer that is refractory to prior anti-PD-(L)1 therapy, and treats them with standard carboplatin/paclitaxel plus infusions of autologous rapamycin-resistant Th1/Tc1-polarized T cells (RAPA-201, designed to resist immunosuppression and checkpoint inhibition), with anti-PD1 maintenance (pembrolizumab) in selected cohorts. Eligible patients must have good performance status and adequate organ function for apheresis.

ClinicalTrials.gov ID: NCT05144698

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic pancreatic or non-small cell lung cancer harboring both MTAP loss and a RAS mutation, previously treated with standard therapies, to receive TNG462 (a selective PRMT5 inhibitor exploiting MTAP-deleted tumor vulnerabilities) combined with either RMC-6236 (a multi-RAS mutant inhibitor) or RMC-9805 (a KRAS G12D-selective inhibitor). Prior treatment with RAS-targeted, PRMT5, or MAT2A inhibitors is not allowed.

ClinicalTrials.gov ID: NCT06922591

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with previously untreated, stage IV NSCLC (squamous or non-squamous, PD-L1 TPS ≥ 1%, no actionable driver mutations) and evaluates combinations of rilvegostomig, a bispecific PD-1/TIGIT inhibitor, with AB248 (a CD8-targeted IL-2 variant) and/or standard therapies including platinum-based chemotherapy and ramucirumab. Patients with prior immunotherapy, actionable genomic alterations, or significant autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT06996782

A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring homozygous MTAP deletion who have progressed after standard therapies, investigating the oral MAT2A inhibitor S095035 as monotherapy and in combination with TNG462, a PRMT5 inhibitor, both of which target vulnerabilities specific to MTAP-deleted cancers. Eligible patients must have good performance status, adequate organ function, and available tumor tissue for genetic confirmation.

ClinicalTrials.gov ID: NCT06188702

A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors harboring a KRAS G12D mutation (including PDAC, NSCLC, and CRC) who have progressed after prior therapy, and evaluates the investigational oral KRAS G12D dual ON/OFF inhibitor VS-7375 as monotherapy and in combination with cetuximab. Key exclusions include prior KRAS G12D inhibitors and active CNS metastases.

ClinicalTrials.gov ID: NCT07020221

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors or pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation who have received prior standard therapies, testing ARV-806, an investigational IV protein degrader specifically targeting mutant KRAS G12D. Patients with prior KRAS G12D/pan-KRAS inhibitor exposure or uncontrolled comorbidities are excluded.

ClinicalTrials.gov ID: NCT07023731

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, advanced, or metastatic NSCLC or SCLC—including both treatment-naïve and previously treated patients—are eligible for this trial evaluating BNT324, a B7-H3-targeted antibody-drug conjugate, in combination with BNT327, a bispecific antibody targeting PD-L1 and VEGF-A. Separate cohorts include NSCLC with and without actionable oncogenic alterations and both first- and later-line treatment settings.

ClinicalTrials.gov ID: NCT06892548

Phase II Study of Diclofenac Salvage in Patients Metastatic Non-Small Cell Lung Cancer With Early Signs of Progression on Single Agent PD(L)-1 Blockade

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Enrolling adults with stage III or IV metastatic non-small cell lung cancer who are experiencing early radiographic progression on at least 12 weeks of single-agent PD-1 or PD-L1 inhibitor immunotherapy, this trial adds diclofenac (a cyclooxygenase-inhibiting NSAID with potential immunomodulatory effects) to ongoing checkpoint inhibitor therapy. Patients must have adequate organ function, ECOG 0-2, and no contraindications to NSAIDs or need for anticoagulation.

ClinicalTrials.gov ID: NCT06731270

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors (excluding primary CNS tumors); for IDE161 monotherapy, patients must have BRCA1/2 or other homologous recombination deficiency gene alterations, while the combination arm is for patients with advanced or recurrent endometrial cancer who have progressed on prior anti–PD-1/L1 therapy. IDE161 is an investigational oral inhibitor of poly(ADP-ribose) glycohydrolase (PARG), targeting DNA repair in HR-deficient tumors, given alone or in combination with pembrolizumab.

ClinicalTrials.gov ID: NCT05787587